Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Glaukos Corporation
GKOS
NYSE·Healthcare·Medical - Devices·Mkt cap $8.1B
$148.34
▲ +7.83%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$73.16 - $148.60
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 32.8% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary micro-scale device platform enabling minimally invasive treatment with reduced surgical trauma
- First-mover advantage in MIGS market with established clinical evidence and broad physician adoption
- Integrated approach combining device technology with pharmaceutical delivery capabilities through iDose TR platform
- Strong intellectual property portfolio protecting core technologies and product innovations
Bear Case
1 risk
- Average volatility.
Growth
Moderate growth ahead
Expanding MIGS market adoption as preferred alternative to traditional glaucoma surgeries with lower complication rates
Value
Deep value opportunity - significant discount to Medical Devices peers
Momentum
Hot
+22.0% over 3m
Quality
Excellent
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying GKOS right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Apr 28, 2026
APR 29, 2026
Reported EPS of -$0.18 vs -$0.30 consensus (+40.0% surprise). Revenue of $150.6M vs $137.0M expected (+9.9%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+40.0%
Next: Apr 28, 2026
Revenue trend · last 8Q
—
—
+28%
+25%
+30%
+38%
+36%
+41%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$95.7M
$96.7M
$105.5M
$106.7M
$124.1M
$133.5M
$143.1M
$150.6M
Margins · last 8Q
Gross
77.9%
Operating
-13.2%
Profit
-13.1%
Wall Street consensus
6 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
$151.50
▲ +2.1% vs $148.34
Latest: Needham · Jun 17, 2026
3 analysts covering